{"entity":{"id":"onvansertib","kind":"drug","name":"Onvansertib","aka":[],"tldr":"Onvansertib is an oral serine/threonine kinase inhibitor from Cardiff Oncology, in registered phase 2 trials for colorectal cancer.","summary":"Onvansertib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Cardiff Oncology, in colorectal cancer. A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Onvansertib","url":"https://clinicaltrials.gov/search?intr=Onvansertib"},{"label":"NCI Drug Dictionary: onvansertib","url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/onvansertib"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":["plk1"],"drugs":[],"companies":["cardiff-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06106308"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Onvansertib is an orally bioavailable, ATP-competitive inhibitor of polo-like kinase 1, which disrupts mitosis and causes G2/M arrest in PLK1-overexpressing cells (NCI Drug Dictionary)."],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"modality":"Oral serine/threonine kinase inhibitor","mechanism":"A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/onvansertib/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"target":[{"id":"plk1","kind":"target","name":"PLK1","route":"/targets/plk1/"}],"company":[{"id":"cardiff-oncology","kind":"company","name":"Cardiff Oncology","route":"/companies/cardiff-oncology/"}],"trial":[{"id":"nct06736717","kind":"trial","name":"Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer","route":"/trials/nct06736717/"},{"id":"nct06106308","kind":"trial","name":"Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab fo","route":"/trials/nct06106308/"},{"id":"nct05450965","kind":"trial","name":"Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer","route":"/trials/nct05450965/"}]}}